|
How Decision Efficiency Redefines Quality
Regulatory writing has evolved more in the past 5 years than in the previous 23 years when the first eCTD guidance reshaped expectations for how sponsors structure and submit information. The move to electronic documents led to wholesale “infobesity” in submission documents. Once submissions shifted from binders to electronic modules, the constraints that once forced concision vanished. Sprawling narratives, dense paragraphs, and an overwhelming volume of “just-in-case” content could be created at virtually no direct cost. In turn, regulatory and clinical research readers did not gain clarity—they gained cognitive load. This shift exposed a deeper truth: regulatory and medical writing was not suffering from a lack of information. Rather the writing was suffering from a lack of decision-oriented design. Our industry has been evolving ever since, moving from text density toward lean writing and now toward decision clarity. Text Density — When Volume Masqueraded as Rigor The early years of application of eCTD created a quiet but powerful shift: once page limits disappeared (or ignored), volume became a proxy for thoroughness. Teams got into the “story telling” business and filled sections with extensive background, descriptions, and narratives about development choices. Exhaustive restatements of data already visible in tables appeared in text whenever the opportunity arose. Text density produced the illusion of rigor. A 200-page Clinical Overview or a 450-page Summary of Clinical Safety looked complete, but regulatory readers had to work hard to locate relevance, reconstruct logic, and discover answers to their questions. The writing provided information, but not orientation. Reviewers encountered paragraphs thick with detail yet thin on meaning. Text density also obscured reasoning. Critical comparisons, implications, and interpretive cues were often buried deep within paragraphs, leaving regulatory readers responsible for making connections the sponsor should have made explicit. This created a systematic drag on regulatory review: more content meant more friction, not more understanding. This era revealed a foundational problem that still affects submissions today: information without structure does not support decisions. Lean Writing — Necessary, but Not Sufficient The industry’s first corrective action to address text density was and still is “lean writing.” Teams recognized that dense passages and exhaustive narrative created reader friction, so the solution became minimalism (a topic I have written about here on multiple occasions). The shift has helped, but only at the surface level. Lean writing reduced noise, but it did not facilitate understanding. Many documents now look cleaner but still lack decision orientation. A protocol may present short, well- edited sentences yet hide the operational logic reviewers and sites need. A Clinical Overview may be concise yet still require the reviewer to infer why a finding matters or what the sponsor means when they use the term “clinically meaningful” 23 times in the document. A Summary of Clinical Safety may use lean prose but avoid interpreting the patterns revealed in its own tables. Lean writing is a valuable improvement—no question. But the gains remain shallow when the deeper reasoning structure stays unchanged. Lean prose without interpretive clarity still forces the reader to supply missing logic, rebuild context, or hunt for warrants behind claims. This era revealed a second truth: reduced text volume does not guarantee reduced cognitive burden. Lean writing improves readability, but not necessarily regulatory decision-making. Decision Clarity — The New Standard The next stage in the evolution of regulatory writing is not shorter text—it is supporting clearer decisions. Decision clarity shifts the writer’s goal from reducing words to reducing the reviewer’s cognitive load. The measure of quality becomes simple: How efficiently can a regulatory reader reach a defensible conclusion? Decision clarity begins where lean writing ends. Once excess words are removed, the real work starts: structuring the logic behind claims, interpreting evidence directly, and guiding the reviewer through the reasoning that connects data to decisions. Decision clarity requires writers to treat every paragraph as an opportunity to make meaning visible. Documents that achieve decision clarity share three characteristics: Lead with the conclusion. Sections begin with the “So what?”—the decision-relevant point—followed by the reasoning and evidence that justify the position. Reviewers never have to hunt for the point the sponsor is trying to make. Make reasoning explicit. Interpretation is not implied or buried. Writers connect effect size to clinical relevance, exposure to safety implications, uncertainty to risk boundaries, and subgroup findings to generalizability. The reviewer is never forced to supply missing logic. Create visible decision cues. Reviewers see the logic trail: purpose → evidence → interpretation → implication. Headings signal meaning, not merely topics. Tables are interpreted directly. Comparisons are explicit. Warrants behind key messages and claims are stated, not assumed. Decision clarity transforms submission documents from passive repositories of information into decision tools. Reviewers gain momentum instead of friction. The thinking of the writing team is traceable. This era reveals the third and most important truth: clarity of reasoning—not speed to final draft, not minimalism—is the core determinant of regulatory decision efficiency. +++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++++ We solved the wrong problem for 20+ years. eCTD made it easy to add content—but not to create clarity. The next leap isn’t faster drafting or cleaner sentences. It’s decision clarity: writing that reduces friction and accelerates reviewer reasoning. Check out my new article in the Decision Efficiency series: www.linkedin.com/pulse/from-text-density-decision-clarity-gregory-cuppan-bvwvc
0 Comments
Leave a Reply. |
AuthorGregory Cuppan is the Managing Principal of McCulley/Cuppan Inc., a group he co-founded. Mr. Cuppan has spent 30+ years working in the life sciences with 20+ years providing consulting and training services to pharmaceutical and medical device companies and other life science enterprises. Archives
December 2025
Categories |
RSS Feed